Free Trial

Oculis Holding AG (NASDAQ:OCS) Short Interest Update

Oculis logo with Medical background

Oculis Holding AG (NASDAQ:OCS - Get Free Report) was the recipient of a large growth in short interest in the month of May. As of May 31st, there was short interest totalling 21,700 shares, a growth of 29.9% from the May 15th total of 16,700 shares. Based on an average daily volume of 37,400 shares, the short-interest ratio is currently 0.6 days. Currently, 0.1% of the company's shares are sold short.

Oculis Price Performance

Shares of Oculis stock traded down $0.20 during trading on Friday, reaching $19.28. 45,000 shares of the company traded hands, compared to its average volume of 45,243. The firm has a market capitalization of $841.76 million, a PE ratio of -7.30 and a beta of 0.35. Oculis has a 1-year low of $10.79 and a 1-year high of $23.08. The company has a 50 day moving average price of $18.55 and a 200-day moving average price of $18.97.

Oculis (NASDAQ:OCS - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.77) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.26). Oculis had a negative net margin of 13,788.70% and a negative return on equity of 92.95%. The company had revenue of $0.32 million for the quarter, compared to analyst estimates of $0.22 million. Equities research analysts expect that Oculis will post -2.09 earnings per share for the current year.

Institutional Investors Weigh In On Oculis

A number of hedge funds have recently added to or reduced their stakes in the company. Bellevue Group AG bought a new position in shares of Oculis in the 4th quarter worth $170,000. XTX Topco Ltd acquired a new position in Oculis during the fourth quarter worth $225,000. Kestra Private Wealth Services LLC bought a new position in shares of Oculis in the first quarter valued at $234,000. Geode Capital Management LLC lifted its stake in shares of Oculis by 12.0% in the fourth quarter. Geode Capital Management LLC now owns 16,744 shares of the company's stock valued at $284,000 after buying an additional 1,800 shares in the last quarter. Finally, Citadel Advisors LLC acquired a new position in shares of Oculis during the fourth quarter valued at about $389,000. Institutional investors and hedge funds own 22.30% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on OCS shares. Chardan Capital lifted their target price on shares of Oculis from $28.00 to $33.00 and gave the stock a "buy" rating in a research note on Friday, May 9th. HC Wainwright lifted their price objective on Oculis from $29.00 to $32.00 and gave the stock a "buy" rating in a research report on Thursday, April 17th. Finally, Robert W. Baird upped their target price on Oculis from $37.00 to $41.00 and gave the company an "outperform" rating in a research report on Thursday, March 13th.

Get Our Latest Stock Report on OCS

Oculis Company Profile

(Get Free Report)

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.

Read More

Should You Invest $1,000 in Oculis Right Now?

Before you consider Oculis, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oculis wasn't on the list.

While Oculis currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Don’t Miss These Top 3 Defense Stocks Set To Gain
Triple-Digit Gains: These 4 Nuclear Stocks Have Even More Upside Ahead
3 Made in America Stocks Under $20 You Need to See!

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines